ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–13. doi:10.3322/caac.v69.1.
   PubMed Web of Science ®Google Scholar
• Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer. 2008;113(7 Suppl):1911–1932. doi:10.1002/cncr.23654.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965. doi:10.1016/S1470-2045(16)30066-3.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582. doi:10.1038/nature14129.
   PubMed Web of Science ®Google Scholar
• Eytan DF, Snow GE, Carlson S, Derakhshan A, Saleh A, Schiltz S, Cheng H, Mohan S, Cornelius S, Coupar J, et al. SMAC mimetic birinapant plus radiation eradicates human head and neck cancers with genomic amplifications of cell death genes FADD and BIRC2. Cancer Res. 2016;76(18):5442–5454. doi:10.1158/0008-5472.CAN-15-3317.
   PubMed Web of Science ®Google Scholar
• Xiao R, Allen CT, Tran L, Patel P, Park S-J, Chen Z, Van Waes C, Schmitt NC. Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. OncoImmunology. 2018;7(9):e1471440. doi:10.1080/2162402X.2018.1471440.
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer. 2010;10(8):561–574. doi:10.1038/nrc2889.
   PubMed Web of Science ®Google Scholar
• Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature. 2011;471(7338):363–367. doi:10.1038/nature09852.
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669–681. doi:10.1016/j.cell.2007.10.030.
   PubMed Web of Science ®Google Scholar
• Oberst A, Green DR. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nat Rev Mol Cell Biol. 2011;12(11):757–763. doi:10.1038/nrm3214.
   PubMed Web of Science ®Google Scholar
• Moquin DM, McQuade T, Chan FK. CYLD deubiquitinates RIP1 in the TNFalpha-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS One. 2013;8(10):e76841. doi:10.1371/journal.pone.0076841.
   PubMed Web of Science ®Google Scholar
• Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell’s decision to live or die. Cell Death Differ. 2007;14(3):400–410. doi:10.1038/sj.cdd.4402085.
   PubMed Web of Science ®Google Scholar
• Salvesen GS, Duckett CS. Apoptosis: IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2002;31:5045–5060.
   Google Scholar
• Derakhshan A, Chen Z, Van Waes C. Therapeutic small molecules target inhibitor of apoptosis proteins in cancers with deregulation of extrinsic and intrinsic cell death pathways. Clin Cancer Res. 2017;23(6):1379–1387. doi:10.1158/1078-0432.CCR-16-2172.
   PubMed Web of Science ®Google Scholar
• Brands RC, Herbst F, Hartmann S, Seher A, Linz C, Kübler AC, Müller-Richter UDA. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines. Clin Oral Investig. 2016;20(9):2325–2332. doi:10.1007/s00784-016-1741-3.
   PubMed Web of Science ®Google Scholar
• Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11(2):109–124. doi:10.1038/nrd3627.
   PubMed Web of Science ®Google Scholar
• Matzinger O, Viertl D, Tsoutsou P, Kadi L, Rigotti S, Zanna C, Wiedemann N, Vozenin MC, Vuagniaux G, Bourhis J. The radiosensitizing activity of the SMAC-mimetic, debio 1143, is TNFalpha-mediated in head and neck squamous cell carcinoma. Radiother Oncol. 2015;116(3):495–503. doi:10.1016/j.radonc.2015.05.017.
   PubMed Web of Science ®Google Scholar
• Dougan SK, Dougan M. Regulation of innate and adaptive antitumor immunity by IAP antagonists. Immunotherapy. 2018;10(9):787–796. doi:10.2217/imt-2017-0185.
   PubMed Web of Science ®Google Scholar
• Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, et al. Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nat Commun. 2017;8. doi:10.1038/ncomms14278.
   PubMed Web of Science ®Google Scholar
• Kearney CJ, Lalaoui N, Freeman AJ, Ramsbottom KM, Silke J, Oliaro J. PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF. Cell Death Differ. 2017;24(10):1705–1716. doi:10.1038/cdd.2017.94.
   PubMed Web of Science ®Google Scholar
• Gentle IE, Moelter I, Lechler N, Bambach S, Vucikuja S, Häcker G, Aichele P. Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice. Blood. 2014;123(5):659–668. doi:10.1182/blood-2013-01-479543.
   PubMed Web of Science ®Google Scholar
• Clancy-Thompson E, Ali L, Bruck PT, Exley MA, Blumberg RS, Dranoff G, Dougan M, Dougan SK. IAP antagonists enhance cytokine production from mouse and human iNKT cells. canimm.0490.2017; 2017.
   Google Scholar
• Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, et al. IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med. 2010;207(10):2195–2206. doi:10.1084/jem.20101123.
   PubMed Web of Science ®Google Scholar
• Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016;22(12):1411–1420. doi:10.1038/nm.4229.
   PubMed Web of Science ®Google Scholar
• Ward GA, Lewis EJ, Ahn JS, Johnson CN, Lyons JF, Martins V, Munck JM, Rich SJ, Smyth T, Thompson NT, et al. ASTX660, a novel non-peptidomimetic antagonist of cIAP1/2 and XIAP, potently induces TNFα-dependent apoptosis in cancer cell lines and inhibits tumor growth. Mol Cancer Ther. 2018;17(7):1381–1391. doi:10.1158/1535-7163.MCT-17-0848.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21(10):1128–1138. doi:10.1038/nm.3944.
   PubMed Web of Science ®Google Scholar
• Terenzi A, Pirker C, Keppler BK, Berger W. Anticancer metal drugs and immunogenic cell death. J Inorg Biochem. 2016;165:71–79. doi:10.1016/j.jinorgbio.2016.06.021.
   PubMed Web of Science ®Google Scholar
• Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97–111. doi:10.1038/nri.2016.107.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989–2003. doi:10.1084/jem.20101158.
   PubMed Web of Science ®Google Scholar
• Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011;208(10):2005–2016. doi:10.1084/jem.20101159.
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3(9):e955691. doi:10.4161/21624011.2014.955691.
   PubMed Web of Science ®Google Scholar
• Montico B, Nigro A, Casolaro V, Dal Col J. Immunogenic apoptosis as a novel tool for anticancer vaccine development. Int J Mol Sci. 2018;19(2):594. doi:10.3390/ijms19020594.
   PubMed Web of Science ®Google Scholar
• Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingelhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol Head Neck Surg. 2007;133(5):495–502. doi:10.1001/archotol.133.5.495.
   PubMedGoogle Scholar
• Judd NP, Allen CT, Winkler AE, Uppaluri R. Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngol Head Neck Surg. 2012;147(3):493–500. doi:10.1177/0194599812442037.
   PubMed Web of Science ®Google Scholar
• Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A. 1989;86:10104–10107. doi:10.1073/pnas.86.24.10104.
   PubMed Web of Science ®Google Scholar
• Cash H, Shah S, Moore E, Caruso A, Uppaluri R, Van Waes C, Allen C. mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. Oncotarget. 2015;6(34):36400–36417. doi:10.18632/oncotarget.v6i34.
   PubMedGoogle Scholar
• Moore EC, Cash HA, Caruso AM, Uppaluri R, Hodge JW, Van Waes C, Allen CT. Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers. Cancer Immunol Res. 2016;4(7):611–620. doi:10.1158/2326-6066.CIR-15-0252.
   PubMed Web of Science ®Google Scholar
• Morisada M, Moore EC, Hodge R, Friedman J, Cash HA, Hodge JW, Mitchell JB, Allen CT. Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. Oral Oncol. 2017;71:87–94. doi:10.1016/j.oraloncology.2017.06.005.
   PubMed Web of Science ®Google Scholar
• Fischer K, Tognarelli S, Roesler S, Boedicker C, Schubert R, Steinle A, Klingebiel T, Bader P, Fulda S, Ullrich E, et al. The smac mimetic BV6 improves NK cell-mediated killing of rhabdomyosarcoma cells by simultaneously targeting tumor and effector cells. Front Immunol. 2017;8:202. doi:10.3389/fimmu.2017.00202.
   PubMed Web of Science ®Google Scholar
• Xiao R, An Y, Ye W, Derakhshan A, Cheng H, Yang X, Allen C, Chen Z, Schmitt NC, Van Waes C, et al. Dual antagonist of cIAP/XIAP ASTX660 Sensitizes HPV(-)and HPV(+) head and neck cancers to TNFalpha, TRAIL, and radiation therapy. Clin Cancer Res. 2019;25:6463–6474. doi:10.1158/1078-0432.CCR-18-3802.
   PubMed Web of Science ®Google Scholar
• Ardani A, Gameiro S, Kwilas A, Donahue R, Hodge J. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 2014;5:9335–9348. doi:10.18632/oncotarget.2429.
   PubMedGoogle Scholar
• Knights AJ, Fucikova J, Pasam A, Koernig S, Cebon JJCI. Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. Cancer Immunol Immunother. 2013;62(2):321–335. doi:10.1007/s00262-012-1342-1.
   PubMed Web of Science ®Google Scholar
• Roehle KDM, Dougan S Augmenting immunity with IAP antagonists in PDAC. In: Annual Meeting and Pre-Conference Programs, Society for Immunotherapy of Cancer; 2018 Nov 7-11, Washington, DC. Abstract P467.
   Google Scholar
• Emeagi PU, Van Lint S, Goyvaerts C, Maenhout S, Cauwels A, McNeish IA, Bos T, Heirman C, Thielemans K, Aerts JL, et al. Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Res. 2012;72(6):1342–1352. doi:10.1158/0008-5472.CAN-11-2400.
   PubMed Web of Science ®Google Scholar
• Tao Z, McCall NS, Wiedemann N, Vuagniaux G, Yuan Z, Lu B. SMAC mimetic debio 1143 and ablative radiation therapy synergize to enhance antitumor immunity against lung cancer. Clin Cancer Res. 2019;25(3):1113–1124. doi:10.1158/1078-0432.CCR-17-3852.
   PubMed Web of Science ®Google Scholar
• Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer G. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology. 2012;1(3):393–395. doi:10.4161/onci.19070.
   PubMed Web of Science ®Google Scholar
• Ding D, Liu H, Qi W, Jiang H, Li Y, Wu X, Sun H, Gross K, Salvi R. Ototoxic effects and mechanisms of loop diuretics. J Otol. 2016;11(4):145–156. doi:10.1016/j.joto.2016.10.001.
   PubMedGoogle Scholar
• Vermeer DW, Coppock JD, Zeng E, Lee KM, Spanos WC, Onken MD, Uppaluri R, Lee JH, Vermeer PD. Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis. Oncotarget. 2016;7(17):24194–24207. doi:10.18632/oncotarget.v7i17.
   PubMedGoogle Scholar
• Gomez-Roca C, Even C, Le Tourneau C, Baste Rotlan N, Delord JP, Sarini J, Vergez S, Teman S, Hoffman C, Rochaix P, et al. Open-label, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the SMAC mimetic debio 1143 in patients with resectable squamous cell carcinoma of the head and neck. In: Proceedings, AACR Annual Meeting; 2019, Apr 14-18, 2018; Atlanta, GA. Philadelphia (PA): AACR; Abstract nr 5001.
   Google Scholar
• Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, Bradford CR, Carey TE. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck. 2010;32(4):417–426. doi:10.1002/hed.21198.
   PubMed Web of Science ®Google Scholar
• Moore E, Clavijo PE, Davis R, Cash H, Van Waes C, Kim Y, Allen C. Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. Cancer Immunol Res. 2016;4(12):1061–1071. doi:10.1158/2326-6066.CIR-16-0104.
   PubMed Web of Science ®Google Scholar
• Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019;4(7). doi:10.1172/jci.insight.126853.
   Web of Science ®Google Scholar
• Clavijo PE, Friedman J, Robbins Y, Moore EC, Smith E, Zauderer M, Evans EE, Allen CT. Semaphorin4d inhibition improves response to immune-checkpoint blockade via attenuation of mdsc recruitment and function. Cancer Immunol Res. 2019;7(2):282–291. doi:10.1158/2326-6066.CIR-18-0156.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61. doi:10.1038/nm1523.
   PubMed Web of Science ®Google Scholar
• Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med. 2012;4(143):143ra199. doi:10.1126/scitranslmed.3003807.
   Web of Science ®Google Scholar
• Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli E, Baracco EE, Galluzzi L, Zitvogel L, Kepp O, et al. Screening of novel immunogenic cell death inducers within the NCI mechanistic diversity set. Oncoimmunology. 2014;3:e28473. doi:10.4161/onci.28473.
   PubMed Web of Science ®Google Scholar